Abstract
Although previous studies indicated a therapeutic benefit from superextended or extended lymph node dissection in bladder cancer patients undergoing radical cystectomy, the first prospective randomized trial could not confirm a significant survival benefit. With multimodal approaches including neoadjuvant or adjuvant chemotherapy as a gold standard, demonstrating any benefit may become even more difficult.
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 617-619 |
Seitenumfang | 3 |
Fachzeitschrift | European Urology Focus |
Jahrgang | 6 |
Ausgabenummer | 4 |
DOIs |
|
Publikationsstatus | Veröffentlicht - 15 Juli 2020 |
Extern publiziert | Ja |